<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838992</url>
  </required_header>
  <id_info>
    <org_study_id>JinanMGH</org_study_id>
    <nct_id>NCT02838992</nct_id>
  </id_info>
  <brief_title>ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia</brief_title>
  <official_title>Multi-center Clinical Study of Immunosuppressants, Cyclophosphamide, And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinan Military General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jining Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Weifang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Hematology and Oncology Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>JINING No.1 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>JIANGXI Provincal People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinhua Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linyi People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Cord Blood Bank</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao Center Medical Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taian City Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yantai Yuhuangding Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yishui Central Hospital of LINYI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jinan Military General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess whether ATG Combined With Cyclophosphamide and cord blood infusion can accelerate
      hematopoietic reconstruction in severe aplastic anemia patients and improve clinical curative
      effect and safety
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aplastic Anemia( AA), is a set of bone marrow hematopoietic dysfunction caused by a variety
      of causes, with hyperplasia of bone marrow hematopoietic cells to reduce whole blood cells
      and peripheral blood at the characteristics of clinical main performance for anemia, bleeding
      and infection. According to the severity of the bone marrow failure and the progress of the
      clinical course ,it is divided into Severe Aplastic Anemia (SAA) and the Non - Severe
      Aplastic Anemia (NSAA).Severe Aplastic Anemia can be divided into two categories: Very Severe
      Aplastic Anemia (VSAA) and Severe Aplastic Anemia (SAA), with the characteristics of rapid
      progress, refractory, poor prognosis, high mortality .The natural course is six months or so,
      and most patients die in a year . Hematopoietic stem cell transplantation and
      immunosuppressive therapy are two main treatment . The former is by far the only possible
      cure. It is recommended as first-line treatments, if patients have a matched sibling donor.
      The recommended age limit is 40 years old. But for those who have no sibling donor or
      patients older than 40 years old, it is recommend the immunosuppressive therapy.

      The investigators have already summarized the effectiveness of rabbit antithymocyte
      immunoglobulin (ATG), cyclophosphamide (Cy) and cyclosporine, A (CsA) and the combination of
      the umbilical cord blood infusion for SAA/VSAA patients without suitable donor, with short
      duration, without long-term immunosuppressive therapy history. The total effectiveness rates
      has improved to 88%, with shorter immunosuppressive maintaining therapy , rapid hematopoietic
      reconstruction, fewer complications. The aim of this study is to further explore whether this
      solution can accelerate hematopoietic reconstruction of SAA/VSAA patients and its clinical
      curative effect and security. This study scheme has been approved by the Jinan military
      region general hospital medical ethics committee.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The total response rate</measure>
    <time_frame>Every 3 months to 24 months</time_frame>
    <description>Response rate is the ratio of CR and PR patients to all evaluated patients at the time point. CR,PR,NR and relapse is evaluated according to the guidelines for the diagnosis and management of adult aplastic anaemia from British Committee for Standards in Haematology (BCSH)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutrophil recovery time</measure>
    <time_frame>From day 0 until the ﬁrst of 3 consecutive days</time_frame>
    <description>The neutrophil recovery day is defined from day &quot;0&quot; until the ﬁrst of 3 consecutive days during which the absolute neutrophil count (ANC) is &gt;0.5×10^9/L, without G-CSF administration .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection rates</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>ATG, Cy and cord blood transfusion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATG 3mg/kg/d for 5 days Cy 50mg/kg/d for 2 days CSA Started from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-400ng/ml One unit of cord blood having no more than 3 HLA-A,B and DRB1 mismatches is transfused 24h after last dose of ATG administration.
Intervention:
Drug: Rabbit ATG, Thymoglobuline (Genzyme) plus Cyclophosphamide plus CSA Biological: Cord blood transfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG and CSA group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ATG 3mg/kg/d for 5 days CSA started from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-400ng/ml Intervention: Drug: Rabbit ATG, Thymoglobuline (Genzyme) plus CSA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabbit ATG, (Genzyme)</intervention_name>
    <description>ATG is an infusion of rabbit-derived antibodies against human T cells, which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia</description>
    <arm_group_label>ATG, Cy and cord blood transfusion group</arm_group_label>
    <arm_group_label>ATG and CSA group</arm_group_label>
    <other_name>Thymoglobuline</other_name>
    <other_name>Anti-thymoeyteGlobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cy</intervention_name>
    <description>Cyclophosphamide is a medication mainly used in chemotherapy. It is an alkylating agent of the nitrogen mustard type</description>
    <arm_group_label>ATG, Cy and cord blood transfusion group</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Cytophosphane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CsA</intervention_name>
    <description>CsA is an immunosuppressant drug widely used in organ transplantation to prevent rejection. It reduces the activity of the immune system by interfering with the activity and growth of T cells</description>
    <arm_group_label>ATG, Cy and cord blood transfusion group</arm_group_label>
    <arm_group_label>ATG and CSA group</arm_group_label>
    <other_name>Ciclosporin A</other_name>
    <other_name>Cyclosporine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cord blood</intervention_name>
    <description>Cord blood is blood that remains in the placenta and in the attached umbilical cord after childbirth. Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders</description>
    <arm_group_label>ATG, Cy and cord blood transfusion group</arm_group_label>
    <other_name>Umbilical cord blood</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ,under the age of 60.

          2. Diagnosis of SAA and VSAA in accordance with the &lt;aplastic anemia, diagnosis and
             treatment expert consensus&gt; Camitta standard (see appendix 1).

          3. Confirmed of heavy and very heavy aplastic anemia within 6 months.

          4. No obvious abnormal liver and kidney function: ALT, AST,≤2.5 times the upper limit of
             normal , serum Creatinine and BUN ≤1.25 times the upper limit of normal

          5. Clear understanding, voluntary to participate in the study, and signed informed
             consent document by the patient or the legal guardian

          6. Willingness and ability to comly with the treatment plan, follow-up and laboratory
             tests as required

        Exclusion Criteria:

          1. Congenital aplastic anemia

          2. Pregnancy or breastfeeding

          3. Participated in other clinical trials within three months

          4. Presence of Any fatal disease, including respiratory failure, heart failure, liver or
             kidney failure, et al

          5. Aplastic anemia caused by the treatment of other malignant tumor treatment

          6. With severe mental illness

          7. With other malignant tumor

          8. Severe infection or the infection difficult to be controlled

          9. Received ATG or cyclosporine A within six months

         10. Severely allergic to biological agents

         11. Any other situation judged by the investigator that the patients inappropriate for
             entry into this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fang Zhou, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The General Hospital Of Jinan Military Command</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fang Zhou, MD</last_name>
    <phone>86-0531-51665316</phone>
    <email>zhoufang1@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhe Yu, MD</last_name>
    <phone>86-0531-51665781</phone>
    <email>doctoryu1120@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The General Hospital Of Jinan Military Command</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fang Zhou, MD</last_name>
      <phone>86-0531-51665316</phone>
      <email>zhoufang1@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Zhe Yu, MD</last_name>
      <phone>86-0531-51665781</phone>
      <email>doctoryu1120@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, Snowden JA, Samarasinghe S, Wood A, Marsh JC; British Society for Standards in Haematology. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016 Jan;172(2):187-207. doi: 10.1111/bjh.13853. Epub 2015 Nov 16. Erratum in: Br J Haematol. 2016 Nov;175(3):546.</citation>
    <PMID>26568159</PMID>
  </reference>
  <results_reference>
    <citation>Zhou F, Ge L, Yu Z, Fang Y, Kong F. Clinical observations on intensive immunosuppressive therapy combined with umbilical cord blood support for the treatment of severe aplastic anemia. J Hematol Oncol. 2011 Jun 10;4:27. doi: 10.1186/1756-8722-4-27.</citation>
    <PMID>21663651</PMID>
  </results_reference>
  <results_reference>
    <citation>Xie LN, Fang Y, Yu Z, Song NX, Kong FS, Liu XM, Zhou F. Increased immunosuppressive treatment combined with unrelated umbilical cord blood infusion in children with severe aplastic anemia. Cell Immunol. 2014 May-Jun;289(1-2):150-4. doi: 10.1016/j.cellimm.2014.03.014. Epub 2014 Apr 3.</citation>
    <PMID>24838091</PMID>
  </results_reference>
  <results_reference>
    <citation>Yu Z, Zhou F, Ge LF, Liu XM, Fang Y, Xie LN, Kong FS, Song NX, Yu QQ. Mechanism of immunosuppressants combined with cord blood for severe aplastic anemia. Int J Clin Exp Med. 2015 Feb 15;8(2):2484-94. eCollection 2015.</citation>
    <PMID>25932194</PMID>
  </results_reference>
  <results_reference>
    <citation>Xie LN, Zhou F. Unexpected unrelated umbilical cord blood stem cell engraft in two patients with severe aplastic anemia that received immunosuppressive treatment: A case report and literature review. Exp Ther Med. 2015 Oct;10(4):1563-1565. Epub 2015 Aug 21.</citation>
    <PMID>26622526</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jinan Military General Hospital</investigator_affiliation>
    <investigator_full_name>Fang Zhou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Umbilical Cord Blood</keyword>
  <keyword>ATG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

